As shown in Figures 7(a) and 7(b), the antifibrotic effectiveness of BAK was further verified by inhibiting the expression level of the cardiac fibrotic marker α-SMA, which was dramatically elevated in the DM group and could be significantly reversed by EX527 treatment. Here, ACTA1 is linked to diabetes mellitus.